Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...

Jefferies analyst Akash Tewari maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...

However, large-cap pharmaceutical companies, including Bristol-Myers Squibb, are seen as well-positioned to mitigate these risks. These are recent developments. This article was generated with the ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 ...

Glen Mills native Jim Cassady has given up his job in digital marketing at Bristol Myers Squibb so he can saturate Delaware ...